

AMENDMENTS

In the Specification

Please replace the paragraph beginning on page 24, line 2, with the following rewritten paragraph:

B ~~A~~ H₂N-Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-CONH₂ (SEQ. ID NO: 11). ~~A~~

In the Claims

Please cancel claim 1, without prejudice or disclaimer.

Please add new claims 28-43 as follows:

B2 28. (New) A purified analog of a T cell-dependent immunogen, said analog comprising an epitope that binds specifically to an antibody to which the immunogen binds specifically, wherein the analog lacks T cell epitopes capable of activating T cells in an individual, and wherein the analog is a polypeptide.

29. (New) The analog of claim 28, further comprising a functional group for coupling to a carrier.

30. (New) The analog of claim 28, wherein the T cell-dependent immunogen is implicated in an antibody-mediated pathology and the individual has the antibody-mediated pathology.

31. (New) A composition comprising the analog of claim 28 and a buffer.